Sase Okihiro, Iwami Tomoko, Sasaki Takeru, Sano Tadashi
You-Me Animal Hospital, Sakura, Japan.
Obihiro University of Agriculture and Veterinary Medicine, Department of Clinical Veterinary Science, Hokkaido, Japan.
Front Vet Sci. 2024 Jul 18;11:1422408. doi: 10.3389/fvets.2024.1422408. eCollection 2024.
Although not registered for feline infectious peritonitis (FIP) in Japan, nucleoside analogs have shown efficacy and we have been offering them to owners of cats with FIP at our clinic since January 2020. The aim of this study was to investigate outcomes in cats with FIP who received GS-441524 or molnupiravir. Diagnosis of FIP was based on clinical signs, laboratory test results, and the presence of feline coronavirus RNA in blood or effusion aspirate. After providing verbal and written information, owners of cats with a presumptive diagnosis of FIP with a were offered antiviral treatment with commercially sourced GS-441524 from June 2020, and either GS-441524 or compounded molnupiravir from January 2022. Dosing was 12.5-25 mg/kg/day for GS-441524 and 20-40 mg/kg/day for molnupiravir, depending on the presence of effusion and neurological and/or ocular signs, and continued for 84 days. Overall, 118 cats with FIP (effusive in 76) received treatment, 59 with GS-4421524 and 59 with molnupiravir. Twenty cats died, 12/59 (20.3%) in the GS-441524 group and 8/59 (13.6%) in the molnupiravir group ( = 0.326), with most deaths within the first 10 days of starting treatment. Among survivors, neurological and ocular signs resolved in all but one cat, who had persistent seizures. Of the cats completing treatment, 48/48 in the GS-441524 group and 51/52 in the molnupiravir group achieved remission. Laboratory parameters normalized within 6 to 7 weeks of starting drug administration. Adverse events, such as primarily hepatic function abnormalities, were transient and resolved without specific intervention. Our data indicate that GS-441524 and molnupiravir show similar effects and safety in cats with FIP.
尽管核苷类似物在日本未注册用于猫传染性腹膜炎（FIP），但已显示出疗效，自2020年1月以来，我们一直在诊所为患有FIP的猫的主人提供此类药物。本研究的目的是调查接受GS-441524或莫努匹拉韦治疗的FIP猫的治疗结果。FIP的诊断基于临床症状、实验室检查结果以及血液或积液抽吸物中猫冠状病毒RNA的存在情况。在提供口头和书面信息后，自2020年6月起，对疑似FIP的猫的主人提供从商业渠道获取的GS-441524进行抗病毒治疗，自2022年1月起提供GS-441524或复方莫努匹拉韦。根据是否存在积液以及神经和/或眼部症状，GS-441524的给药剂量为12.5 - 25毫克/千克/天，莫努匹拉韦为20 - 40毫克/千克/天，并持续84天。总体而言，118只患有FIP的猫（76只出现积液）接受了治疗，59只接受GS-4421524治疗，59只接受莫努匹拉韦治疗。20只猫死亡，GS-441524组中有12/59（20.3%）死亡，莫努匹拉韦组中有8/59（13.6%）死亡（P = 0.326），大多数死亡发生在开始治疗的前10天内。在幸存者中，除一只猫持续癫痫发作外，所有猫的神经和眼部症状均得到缓解。在完成治疗的猫中，GS-441524组的48/48只和莫努匹拉韦组的51/52只实现了病情缓解。实验室参数在开始给药后的6至7周内恢复正常。不良事件，如主要是肝功能异常，是短暂的，无需特殊干预即可缓解。我们的数据表明，GS-441524和莫努匹拉韦在患有FIP的猫中显示出相似的效果和安全性。
